Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nikhil C Munshi, M.D., M.B.,B.S.

Co-Author

This page shows the publications co-authored by Nikhil Munshi and Raphael Szalat.
Connection Strength

4.576
  1. Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2018 01; 32(1):111-119.
    View in: PubMed
    Score: 0.713
  2. Gene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res. 2016 Nov 15; 22(22):5434-5442.
    View in: PubMed
    Score: 0.686
  3. Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. Am Soc Clin Oncol Educ Book. 2016; 35:e442-8.
    View in: PubMed
    Score: 0.646
  4. Genomic heterogeneity in multiple myeloma. Curr Opin Genet Dev. 2015 02; 30:56-65.
    View in: PubMed
    Score: 0.618
  5. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021 09 28; 5(18):3511-3514.
    View in: PubMed
    Score: 0.240
  6. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2021 06 01; 113(6):691-698.
    View in: PubMed
    Score: 0.235
  7. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
    View in: PubMed
    Score: 0.221
  8. Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Adv. 2019 12 10; 3(23):3968-3972.
    View in: PubMed
    Score: 0.212
  9. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6.
    View in: PubMed
    Score: 0.198
  10. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018 08 22; 9(1):3363.
    View in: PubMed
    Score: 0.194
  11. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
    View in: PubMed
    Score: 0.188
  12. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
    View in: PubMed
    Score: 0.174
  13. IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021 11 18; 138(20):1980-1985.
    View in: PubMed
    Score: 0.061
  14. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835.
    View in: PubMed
    Score: 0.052
  15. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170.
    View in: PubMed
    Score: 0.048
  16. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597.
    View in: PubMed
    Score: 0.048
  17. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.